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Abstract
Background: While hybridization based analysis of the cortical transcriptome has provided important insight into the
neuropathology of schizophrenia, it represents a restricted view of disease-associated gene activity based on
predetermined probes. By contrast, sequencing technology can provide un-biased analysis of transcription at nucleotide
resolution. Here we use this approach to investigate schizophrenia-associated cortical gene expression.
Methodology/Principal Findings: The data was generated from 76 bp reads of RNA-Seq, aligned to the reference genome
and assembled into transcripts for quantification of exons, splice variants and alternative promoters in postmortem superior
temporal gyrus (STG/BA22) from 9 male subjects with schizophrenia and 9 matched non-psychiatric controls. Differentially
expressed genes were then subjected to further sequence and functional group analysis. The output, amounting to more
than 38 Gb of sequence, revealed significant alteration of gene expression including many previously shown to be
associated with schizophrenia. Gene ontology enrichment analysis followed by functional map construction identified three
functional clusters highly relevant to schizophrenia including neurotransmission related functions, synaptic vesicle
trafficking, and neural development. Significantly, more than 2000 genes displayed schizophrenia-associated alternative
promoter usage and more than 1000 genes showed differential splicing (FDR,0.05). Both types of transcriptional isoforms
were exemplified by reads aligned to the neurodevelopmentally significant doublecortin-like kinase 1 (DCLK1) gene.
Conclusions: This study provided the first deep and un-biased analysis of schizophrenia-associated transcriptional diversity
within the STG, and revealed variants with important implications for the complex pathophysiology of schizophrenia.
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Introduction
Schizophrenia is a severely debilitating psychiatric disorder with
a complex etiology that arises from the interplay between genetic
and environmental factors [1–3]. The culmination of these factors
gives rise to a change in gene expression in the central nervous
system (CNS) of individuals with schizophrenia, which may be
associated with the pathophysiology of the disorder. Characterisa-
tion of schizophrenia-associated changes in gene expression has
been accomplished in tissue from a variety of brain regions
including the prefrontal cortex (PFC) [4–13], cerebellum [14],
amygdala [15], hippocampus [16,17], as well as the cingulate
[12,18], temporal [12,14,19], parietal [12], entorhinal [12] and
occipital cortices [12] using microarray based hybridisation. While
much of the focus of this analysis and other studies in the
neuropathology of schizophrenia has been in the PFC, the
temporal cortex is also noteworthy as the grey matter volume in
this region, including the superior temporal gyrus (STG) has been
shown to be decreased in affected individuals [20,21]. This region,
encompassing the primary and secondary auditory cortex, is also
likely to play a significant role in positive symptoms, particularly in
the generation of auditory hallucinations. Existing expression
studies in this region have suggested schizophrenia-associated
deficits in presynaptic function, myelination pathways, neuro-
transmission, neuronal development, energy and metabolisms that
are broadly consistent with expression findings in the PFC and
other cortical regions in schizophrenia [22,23]. In addition, gene
expression patterns across multiple brain regions in schizophrenia
demonstrated that the STG showed the maximal number of
altered transcripts when compared to most of the other regions
implicated in schizophrenia, suggesting the particular vulnerability
of the STG in schizophrenia [12,24]. Thus it is highly likely that
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useful insight into the molecular pathophysiology of schizophrenia
associated with this brain region.
The emergence of second generation sequencing (SGS)
technology has raised the prospect of more comprehensive and
accurate transcriptome analysis, down to nucleotide resolution
[25]. mRNA sequencing generates gigabytes of short read
sequence from cDNA, which are mapped to locations of the
known reference genomes with sequence hits counted to
determine their genomic distribution. While a priori knowledge of
probe design is essential for microarrays, mRNA sequencing is free
from this requirement and provides an unbiased measurement at
single nucleotide resolution with single molecule sensitivity [26].
These features make it possible to accurately profile both gene and
transcript isoform expression and extensively identify alternative
promoter selection and novel splicing variants [27,28].
In the study reported here, we used mRNA sequencing to
profile the transcriptome of STG from cortical grey matter in
subjects with schizophrenia. Despite the significance of the STG in
schizophrenia, gene expression profiling in this brain region has
been carried out less frequently than in the PFC. In this analysis of
post-mortem STG transcripts, we reveal significant schizophrenia-
associated disturbance of genes involved in presynaptic function,
myelination, and energy production. This study also highlights the
potential impact of transcriptional diversity of genes exemplified
by the alternative splicing of doublecortin-like kinase 1 (DCLK1).
The alteration of genes involved in the SNARE complex was also
particularly striking in the context of greater presynaptic
dysfunction implicated by this analysis as previous studies
implicated the abnormalities of SNARE proteins in other brain
regions [29–32].
Results
mRNA sequencing data and sequence coverage
Full length cDNA sequence data amounting to 38.6 billion
nucleotides were generated from the assembly of 76 bp single end
reads derived from 18 mRNA samples using the Illumina Genome
Analyzer II platform. The RNA was extracted from post-mortem
cortical grey matter of STG from the left hemisphere of 9 pairs of
male subjects with schizophrenia and non-psychiatric controls
matched for age, postmortem interval (PMI), and pH (Table 1).
This generated 13.1–39.2 million, high quality 76 bp sequences
per sample. Comparison of the number of reads between these
groups showed no significant difference by Student’s t test
(p=0.426). Sequences were aligned to the human genome hg18
and for each sample, more than 90% mappable reads uniquely
aligned to the reference genome (Table 2). The accepted
alignments were further subjected to transcript level analysis and
the number of transcripts detected in STG differed little between
samples (33,30061,900; p=0.55; Table 2). The median
transcript coverage was 21.0 fold and the minimum and maximum
coverage was 9.3 and 24.4 fold, respectively. All gene expression
values were measured by RPKM, a normalized measure adjusting
the read counts by normalizing for gene length and the total
number of mapped reads for each sample, which facilitates
transparent comparison at transcript levels across samples. After
normalising read counts by RPKM, the gene expression values
were made comparable across all samples, as exemplified by the
similar distributions of gene expression values of representative
sample C26 and S26 (Figure 1).
Gene expression analysis
Analysis of differentially expressed genes (DEGs) identified 772
significantly altered genes (False Discovery Rate/FDR,0.05;
FDR is a widely used statistical method for multiple test
correction) in schizophrenia subjects compared to controls (Table
S1), with 398 genes down-regulated and 374 up- regulated. The
fold change ranges from 230.8 to 14.7, and 58% of DEGs
displayed a change of more than 61.2 fold. A substantial
proportion of these DEGs (9%) have been the subject of genetic
association studies in schizophrenia (http://www.szgene.org/)
[33], which were highlighted in bold font in Table S1. The
identified DEGs were then compared to the previously compiled
post-mortem microarray data, which listed prominent and
concordant gene expression differences replicated in at least two
microarray studies in schizophrenia across various cortical regions,
with some genes confirmed at protein levels as well [34,35]. This
compiled list contained 36 validated genes categorized to 10
functional groups highly relevant to schizophrenia. Half of these
genes were also present in our DEG list covering each functional
group, which included YWHAH and YWHAE from 14-3-3 gene
family; CCK, GAD1 (Figure 2), and HINT1 related to GABA
function; GLUL associated with glutamate function; two immune
genes IFITM2 and IFITM3; myelin and oligodendrocyte genes
MAG, CNP, and TF; signalling and synaptic genes RGS4 and
SYN2; three genes involved in mitochondrial and metabolic
functions (PRDX2, ALDOC, and MDH1); neuronal plasticity
gene GAP43; and stress gene MT2A (Table 3). As to the
comparison between DEGs detected here and those previously
reported in temporal cortex by microarray studies, consistent
changes were found for 14-3-3 family gene YWHAH [14],
oligodendrocyte- and myelin-related genes MAG, PLLP, PLP1,
CNP, and TF [19,36], and genes involved in signalling and
synaptic function RGS4 and GRINA [22].
Validation of differentially expressed genes by
quantitative PCR (qPCR)
To confirm the DEGs from the mRNA sequencing approach,
mRNA expression levels of the selected DEGs were measured by
conventional TaqMan based qPCR assays in a larger cohort
consisting of 28 schizophrenia cases and 28 matched non-
psychiatric controls (including the original samples). The three
genes tested, including B-cell translocation gene 2 (BTG2, also
known as NGF-inducible anti-proliferative protein), dual specific
phosphatase (DUSP1), and early growth response 4 (EGR4) were
all found to be significantly down-regulated with fold changes of
22.27 (p=0.00014), 21.94 (p=0.004) and 22.35 (p=0.032),
respectively (Figure 3), which was all in accordance with the fold
changes detected by RNA-sequencing (Table S1). In addition,
BTG2 and DUSP1 expression levels showed no correlation with
age, PMI or pH. Despite the correlation with age (Spearman’s
rho=20.454; p=0.001), EGR4 expression remained significantly
associated with schizophrenia when age was used as a covariate
(ANCOVA).
Gene ontology (GO) enrichment analysis and functional
map construction
All DEGs were subjected to GO term enrichment analysis that
revealed 55 and 113 GO terms significantly enriched at the
stringent cut off level of FDR,0.05 and relaxed cut off level of
FDR,0.4, respectively (Table S2). To identify the major
functional themes, enriched GO terms were organised into a
functional network (Figure 4) using Enrichment Map software
[37]. The ‘seed’ GO terms for the network at FDR,0.05 were
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with a more relaxed threshold of 0.05#FDR,0.4 were also
included to show the minor satellite networks. This analysis
revealed six functional clusters including, (1) microtubule related
motility, (2) mitochondrial function and ATP production, (3)
ribosome and translation activity, (4) neurotransmission related
functions, (5) synaptic vesicle trafficking, and (6) neural develop-
ment.
Identification of core enrichment genes
Clusters 4, 5, and 6 were directly relevant to neurological
function and therefore may also be particularly relevant to the
pathophysiology of schizophrenia. For example cluster 4, named
‘neurotransmission related functions’, contained 40 core enrich-
ment genes derived from the union of the GO terms synaptic
transmission, synaptosome, and neurotransmitter secretion (Ta-
ble S3). This consisted of 6 genes encoding for receptors or ion
channels including the cholinergic receptor CHRNE, sodium
channel SCN1B, potassium channel KCNMB1, GABA receptors
GABRA5 and GABRD, and hypocretin receptor HCRTR1.
Cluster 4 also contained the kinase genes PRKACA encoding
protein PKA, PPP3CA encoding protein CaN, and PRKCG
encoding protein PKC, which have been shown to participate in
the long-term potentiation pathway.
Cluster 5, ‘synaptic vesicle trafficking’, consisted of 42 core
enrichment genes derived from the union of GO terms synaptic
vesicle, synaptic vesicle membrane, synapse, syntaxin binding,
syntaxin-1 binding, receptor-mediated endocytosis, and regulation
of exocytosis (Table S4). Twelve of these (29%) are directly
involved in synaptic vesicle trafficking including synaptotagmin I,
II, III (SYT1, SYT2, SYT3), synaptobrevin 1 (VAMP1),
synaptosomal-associated protein (SNAP25), synaptophysin (SYP),
synapsin II (SYN2), N-ethylmaleimide-sensitive factor (NSF), NSF
attachment protein (NAPA), regulating synaptic membrane
exocytosis 3 (RIMS3), complexin 1 and 2 (CPLX1, CPLX2)
(Figure 5). On the postsynaptic side of the equation, this cluster
contained another 5 genes including a glutamate receptor
GRIN3B, zinc activated ligand-gated ion channel (ZACN), and
the receptors described in cluster 5 (CHRNE, GABRA5 and
GABRD).
Cluster 6, or ‘neural development’, consisted of 78 core
enrichment genes derived from the union of all the 12 GO terms
related to neural development (Figure 4; Table S5). Eight of
these 78 genes (.10%) are related to myelination, including
CLDN11, CNP, MAG, MBP, MOBP, PLLP, PLP1, and OLIG1.
There was also representation from neuroactive kinases, with
genes encoding cGMP-dependent PRKG1, doublecortin-like
kinase 1 DCLK1, creatine kinase CKB, and phosphatidylinosi-
tol-4-phosphate 5-kinase PIP5K1C.
Analysis of transcript isoforms
Alternative splicing of primary transcripts and alternative
promoter usage are important aspects of disease-associated
transcriptomes that can be gleaned on a whole genome basis by
deep sequencing. We examined transcriptional diversity of genes
in schizophrenia and found that more than 2000 Ensembl genes
displayed significant alternative promoter usage in schizophrenia
(FDR,0.05; Table S6) and 1032 genes showed differential
splicing between cases and controls (FDR,0.05; Table S7). We
further investigated whether these alternative promoter usage/
splicing events were also present in the core enrichment genes
highlighted in Figure 4, which are directly relevant to
neurological function. Alternative promoter usage was detected
in 7 core enrichment genes including GABRA5, HCRTR1, MBP,
PRKG1, SYP, SYT1, and DCLK1; differential splicing was found
in PLP1 and DCLK1. Further details of the differential splicing in
PLP1 and DCLK1 were presented below.
Four different DCLK1 transcriptional forms were present in
both groups, namely D01 (ENST00000399319), D02
(ENST00000360631), D03 (ENST00000379893) and D04
(ENST00000379892). These 4 isoforms are generated from 3
alternative promoters and their TSS are referred to as TSSI
(ENST00000379893), TSSII (ENST00000399319), and TSSIII
(ENST00000360631 and ENST00000379892) (Figure 6). Differ-
ential promoter usage analysis revealed 1.1-fold down-regulation
of TSSI usage and 1.2-fold up-regulation of TSSIII usage in
schizophrenia compared to controls with FDR,0.05. Under the
control of TSSIII, significant alternative splicing between the two
isoforms, D02 and D04, was identified with the full length variant
D02 showing 5.5-fold up-regulation in schizophrenia cases
Figure 1. Histogram showing the distribution of gene expression values (in log2RPKM) for all genes in representative samples C26
and S26. The gene expression levels were first normalized to RPKM values and then log2 transformed as shown on x axis. Y axis indicates the
number of genes with expression values falling in the particular log2RPKM intervals. This figure shows the similar distributions of gene expression
values for all genes between C26 and S26.
doi:10.1371/journal.pone.0036351.g001
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36351(FDR,0.05). For the allelic expression within D02 and D04
isoforms, further inspection of the sequencing data at nucleotide
resolution revealed a 2-fold increase and 3-fold decrease in the
representation of the AA and GG genotype, respectively, at
rs2296645 in schizophrenia compared to controls. While these
changes are not statistically significant, because of the sample size,
they illustrate the potential for mRNA sequencing to inform on
expression by genotype effect, allelic expression information, and
parent of origin effects, with significant advantages for larger
studies.
As to PLP1, this gene spans about 17 kb on chromosome X
q22.2 and contains seven exon, which encodes both the 277 amino
acid proteolipid protein 1 PLP (corresponding to
ENST00000303958) and its 242 amino acid isoform, DM20
(corresponding to ENST00000361621). These two isoforms were
generated from the same promoter and they differ from each other
only in the splicing of exon 3. While exon 3 of both forms starts at
102928049 bp on chromosome X, the former ends at
102928311 bp, whereas the latter ends at 102928206 bp. These
two transcriptional forms were detected in both groups, and
alternative splicing analysis revealed that schizophrenia patients
significantly up-regulated the PLP form by 1.1 fold change
(FDR,0.05) and down-regulated the DM20 form by 1.3 fold
change (FDR,0.05).
Discussion
Our study provides the first high-resolution transcriptome
profiling of the STG from subjects with schizophrenia. An average
of 28 million random cDNA sequence reads for each of the 18
samples was generated from 76 bp reads. This delivered sufficient
sequence coverage (median 21.0 fold) for transcriptome profiling
[27], and provided an unparalleled assessment of the transcrip-
tional complexity in the human STG. For each sample, more than
90% of the total mapped reads uniquely mapped to the reference
genome allowing the identification of a comprehensive panel of
DEGs and the incidence of alternative promoter usage and
splicing variation associated with schizophrenia.
This analysis revealed that the expression of 772 genes was
significantly different between cases and controls. These DEGs
covered half of the previously highlighted genes with prominent
and concordant expression change in schizophrenia, detected by
at least two microarray studies across various brain regions [34].
This level of consistency between genome wide expression studies
was unexpected as previous comparisons between microarray
studies typically show more heterogeneity. This concordance
between mRNA sequencing and microarray technology is
encouraging and suggests there is validity in this approach. Our
sequencing data was also supported by qPCR analysis of three
genes including DUSP1, BTG2, and EGR4. Interestingly, in rats
both cortical BTG2 and DUSP1 expression has been shown to be
sensitive to phencyclidine, a noncompetitive antagonist of NMDA
receptors [38]. Further comparison between mRNA sequencing
analysis and existing microarray data both across the various brain
regions and within the temporal cortex revealed three groups of
genes consistently changed in schizophrenia including 14-3-3
family gene, oligodendrocyte- and myelin-related genes, and genes
involved in signalling and synaptic function. Furthermore, for the
remaining seven groups of genes ranging from GABA function to
ubiquitin and stress genes derived from microarray studies
(Table 3), at least one gene was found to be overlapped in our
DEG list. This overlapping coverage in each functional group was
broadly consistent with previous characterization of schizophrenia
as a disease of synaptic, oligodendroglial, and metabolic origin. In
addition to the comparisons at the discrete gene level, GO
enrichment analysis at the gene set level was further carried out to
explore the broad areas of schizophrenia dysfunction. This
enrichment analysis revealed 55 and 113 over-represented GO
terms in schizophrenia at a significance level of FDR,0.05 and
FDR,0.4, respectively. These GO terms enriched in schizophre-
nia were organised into a network consisting of 6 functional
Figure 2. RNA sequencing reads of representative schizophrenia (S25) and control (C25) samples mapping to GAD1 gene. Y-axis
indicates how many reads covering each base along the transcript. The schematic representations of the Ensembl transcripts for GAD1 are shown in
brown at the bottom of the figure. This figure shows the difference in read counts covering GAD1 gene between the schizophreina representative
sample S25 and the control representative sample C25.
doi:10.1371/journal.pone.0036351.g002
Sequencing of STG Transcriptome in Schizophrenia
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e36351clusters including microtubule related motility, ribosome and
translation activity, mitochondrial function and ATP production,
neurotransmission related functions, synaptic vesicle trafficking,
and neural development.
Most striking was the simultaneous detection of 12 genes
encoding SNARE complex associated proteins derived from the
cluster of synaptic vesicle trafficking, which suggested a prominent
role of SNARE complex in presynaptic dysfunction in schizo-
phrenia. Two core SNARE proteins, the synaptosomal-associated
protein of 25 kDa (SNAP25) and the vesicle-associated membrane
protein (VAMP1, also known as synaptobrevin), were both
significantly down-regulated in schizophrenia. The interaction of
SNAP25 and syntaxin-1A with VAMP1 leads to the formation of
the core SNARE complex between the vesicle and presynaptic
terminal membranes [39]. Furthermore, 10 SNARE-interacting
proteins involved in regulation of vesicle release and recycling
were differentially expressed. These genes included: (1) 2 complex-
ins (CPLX1 and CPLX2) and 3 synaptotagmins (SYT1, SYT2,
Table 3. Half of the differentially expressed genes validated by at least two microarray studies in schizophrenia were also
significantly altered in this study.
Functional category Gene symbol
1 Gene description Detection
2
14-3-3 gene family YWHAH 14-3-3 protein eta Yes
14-3-3 gene family YWHAB 14-3-3 protein beta No
14-3-3 gene family YWHAE 14-3-3 protein epsilon Yes
14-3-3 gene family YWHAG 14-3-3 protein gamma No
14-3-3 gene family YWHAQ 14-3-3 protein theta No
14-3-3 gene family YWHAZ 14-3-3 protein zeta No
GABA function CCK cholecystokinin Yes
GABA function GAD1 Glutamic acid decarboxylase 1 (67 kDa) Yes
GABA function HINT1 Histidine triad nucleotide binding protein 1 Yes
Glutamate function GLUL Glutamate-ammonia ligase Yes
Glutamate function GLS Glutaminase, phosphate activated No
Glutamate function BDNF Brain-derived neurotrophic factor No
Glutamate function NTRK2 Tropomyosin receptor related kinase 2, TrkB No
Glutamate function GRIA2 Glutamate receptor, ionotrophic, AMPA 2 No
Immune genes IFITM2 interferon induced transmembrane protein 2 Yes
Immune genes IFITM3 Interferon induced transmenbrane protein 3 Yes
Immune genes SERPINA3 Serpin peptidase inhibitor, clade A(alpha-1 antiproteinase, antitrypsin),
member 3
No
Metabolic function MDH1 Malate dehydrogenase 1 Yes
Metabolic function ALDH7A1 Aldehyde dehydrogenase family 7 member A1 No
Mitochondrial function VDAC1 Voltage-dependent anion channel 1 No
Mitochondrial function ENO1 Alpha enolase No
Mitochondrial function PRDX2 Peroxiredoxin-2 Yes
Mitochondrial function ALDOC Fructose biphosphate aldolase C Yes
Myelin and Oligodendrocyte MAG Myelin associatedd glycoprotein Yes
Myelin and Oligodendrocyte CNP 29,39-cyclic nucleotide 39 phosphodiesterase Yes
Myelin and Oligodendrocyte TF Transferrin Yes
Neuronal plasticity Gene BASP1 Brain acid soluble protein 1 No
Neuronal plasticity Gene DPYSL2 ihydropyrimidinase related protein 2 No
Neuronal plasticity Gene GAP43 Growth-associated protein 43 Yes
Neuronal plasticity Gene CALB1 Calbindin 1 No
Neuronal plasticity Gene CHRM4 Muscarinic 4 receptor No
Signalling and Synaptic RGS4 Regulator of g protein signaling 4 Yes
Signalling and Synaptic SYN2 Synapsin II Yes
Ubiquitin gene and stress UCHL1 Ubiquitin carboxyl-terminal esterase L1 (Ubiquitin thiolesterase) No
Ubiquitin gene and stress MT1X Metallothionein 1X No
Ubiquitin gene and stress MT2A Metallothionein 2A Yes
1Gene symbol: the previously compiled post-mortem microarray data since 2000, which listed prominent and concordant gene expression differences replicated in
multiple studies of schizophrenia across various cortical regions [34,35].
2Detection indicated whether the gene was present in the DEGs we detected in this study. Around half of the differentially expressed genes in schizophrenia confirmed
previously in two or more microarray studies were also observed here by sequencing.
doi:10.1371/journal.pone.0036351.t003
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[40,41]; (2) one of the synapsins (SYN2) which are involved in
vesicle tethering and controlling the number of vesicles available
for release [42]; (3) synaptophysin (SYP) which binds synapto-
brevin (VAMP1) and plays a role in the control of exocytosis [43];
(4) one of the RIM family members (RIMS3) which interacts with
voltage-dependent Ca
2+ channels and regulates neurotransmitter
vesicle anchoring [44]; and (5) NSF and NAPA(SNAP-a) which
bind and then dissociate SNARE complexes for synaptic vesicle
recycling [45]. Though the impact of antipsychotic treatment on
this altered gene expression is unclear, recent studies suggested
that at least some of the changes (down-regulation of SNAP25,
VAMP1, and SYT2; up-regulation of SYP and CPLX1) are
unlikely to arise from the treatment, as animal models showed that
haloperidol and/or clozapine increased SNAP25, VAMP, and
SYT2 levels, while decreased SYP and CPLX1 levels [46–49].
Although altered expression of transcripts encoding presynaptic
secretory machinery including SYN2, NSF, synaptotagmin,
synaptobrevin, synaptophysin, SNAP25, and RIMS have been
reported in various brain regions such as PFC, STG, and
amygdala [7,15,22,50], our study is first to link this mechanism
to a comprehensive panel of genes focused on the function of
SNARE complex in the temporal cortex in schizophrenia.
Consistent with our finding, a recent genomic convergence
analysis of cerebellar cortices in schizophrenia using mRNA
sequencing has identified altered expression of a group of genes
involved in presynaptic vesicular transport [51]. While this study
emphasized genes involved in transport between the trans-Golgi
network and synaptic vesicles, our data highlighted the dysregu-
lation of the SNARE complex and associated proteins directly
involved in synaptic vesicle release. Comparison between these
two mRNA sequencing studies in schizophrenia suggests that
different brain regions may share common pathways relating to
synaptic abnormalities but involve different pathway members.
The deficits in presynaptic gene function could result in
compensatory enhancement of neurotransmission by down-
regulating RGS4 expression, observed here and in previous
microarray studies in PFC and STG [10,22]. The detection of
simultaneous alterations of presynaptic genes and RGS4 is
supportive of the synaptic-neurodevelopmental model of schizo-
phrenia, which suggests that these influences may affect postnatal
synapse formation and pruning, which eventually leads to the
disorder [8].
Further support for the synaptic dysfunction hypothesis of
schizophrenia is suggested by the alteration of genes related to
GABAergic and glutamatergic function, including GABAergic
gene GAD1 (also known as GAD67; Figure 2), GABAA receptor
subunits alpha 5 and delta (GABRA5 and GABRD), and
ionotropic NMDA type glutamate receptor subunit NR3B
(GRIN3B). The reduction of GAD1 observed in our data is one
of the most consistent changes in the schizophrenia neocortex
[52]. Interestingly, while antipsychotic treatment with haloperidol
also impact on GABA receptor subunits and GAD1 expression in
animal studies [53,54], these changes were in the opposite
direction to our observations in schizophrenia.
The co-detection of eight genes involved in neuronal myelina-
tion was also consistent with previous analysis of cortical gene
expression in schizophrenia, which reported dysregulation of
MAG, MBP, MOBP, PLP1, PLLP, and CNP; transcription factor
OLIG1; and oligodendroctye development and myelination
associated gene CLDN11 [4,9,19,36,55]. This group of 8 myelin
related genes, of which 6 significantly down-regulated, provided
further evidence for oligodendrocyte-mediated myelination dys-
function.
Other interesting changes included enriched functional clusters
related to mitochondria function, microtubule, ribosome and
translation and altered expression levels of genes encoding creatine
kinase (CKB) and 14-3-3 family members. It is likely that many of
these genes are functionally intertwined. For example, our
observation of global down-regulation of mitochondrial genes
and genes related to energy metabolism in schizophrenia accords
with previous studies [5,56], and suggests that altered energy
metabolism may be an integral component underlying the cortical
pathophysiology of schizophrenia. The decreased output of ATP
may lead to further consequences such as a reduction in CKB
involved in the storage of high-energy phosphates as observed in
our dataset and bipolar disorder with mitochondrial dysfunction
[57]. Alternatively, decreased energy production will lead to
adaptational changes such as the up-regulation of 14-3-3 family
members (YWHAH and YWHAE), which are involved in
mitochondrial function [58,59].
Coincidently, 9% of DEGs have also been indicated as putative
schizophrenia susceptibility genes (Table S1), including RGS4,
NRGN, and APOE which are all ranked in the top 45 list of
SZGene (http://www.szgene.org). Furthermore, 5 out of 12
SNARE associated genes (SNAP25, CPLX1, CPLX2, SYN2,
and SYP) and 7 myelin related genes, were all implicated in
genetic association/linkage studies [33,60]. These observations
suggested that allelic variation might influence the expression of
these genes as putative expression-quantitative trail loci, however,
further investigation of the association between the differences in
allele frequency and the gene expression would be required to
establish a functional link.
Significant differences in alternative splicing and promoter
usage between cases and controls were identified. Among these,
DCLK1 is of particular interest as it is expressed in the CNS and
plays important roles in brain development [61]. DCLK1 contains
Figure 3. Quantitative real-time PCR validation of genes
altered in schizophrenia. In an extended cohort of n=28
schizophrenia subjects and n=28 non-psychiatric controls, BTG2,
DUSP1 and EGR4, each displayed significantly reduced expression in
the schizophrenia group (black) by qPCR, confirming the changes
observed by mRNA sequencing. BTG2 was down-regulated 22.27 fold
(p=0.00014), DUSP1 was down-regulated 21.94 fold (p=0.004), and
EGR4 was down-regulated 22.35 fold (p=0.032). Statistics were
performed using the Student’s t-test (one-tailed). BTG2 and DUSP1
expression levels did not correlate with demographic variables age, PMI
and pH. EGR4 significantly correlated with age (Spearman’s
rho=20.454, p=0.001) though remained within the threshold for
significance when age was covaried for using ANCOVA. Bars are mean
+SEM. * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0036351.g003
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e36351Figure 4. Network of enriched GO terms derived from differentially expressed genes between schizophrenia and control using
GOseq software. The enriched GO terms are organised as a weighted similarity network, where nodes represent enriched GO terms and weighted
links between the nodes represent the overlap score calculated from the number of genes two GO terms share. By grouping enriched GO terms into
network clusters based on their overlapping extent, 6 distinct functional clusters are identified, which are (1) microtubule related motility, (2)
mitochondrial function and ATP production, (3) ribosome and translation activity, (4) neurotransmission related functions, (5) synaptic vesicle
trafficking, and (6) neural development. GO terms with more overlapping genes are placed closer together; node size represents the number of genes
in the pathway; edge thickness is proportional to the overlap between pathways. Nodes highlighted in pink represent GO terms directly relevant to
the pathophysiology of schizophrenia.
doi:10.1371/journal.pone.0036351.g004
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e36351a doublecortin-like (DCX) domain at the N-terminus and a kinase
domain at C-terminus. The DCX domain at N-terminus was
shown to be involved in the regulation of microtubule polymer-
ization and neuronal migration [62]. One of the C-terminal
isoforms has also been suggested to be a candidate neural plasticity
gene with a potential role in synaptic remodelling [63]. DCLK1
has a few transcript isoforms that include either its full-length, or
only the N-terminal DCX-like region or the kinase-encoding C
terminus alone [64]. Our data suggests some bias for TSSIII usage
in schizophrenia, producing both D02 (full length DCLK1) and
D04 (N-terminal DCL-like region) variants, which have been
shown to prevent apoptosis in neuroblastoma cells [65]. Under
TSSIII, schizophrenia subjects had a higher percentage of D02
variants (case 34.4%) than the controls (6.3%). Interestingly,
DCLK1 expression was shown to be increased in the mouse brain
by clozapine and olanzapine, suggesting that reduction observed
in the STG was not likely to be a result of antipsychotic
medication [53].
In addition, we also observed the differential splicing of PLP1
between cases and controls. This gene is noteworthy as it encodes
one of the major components of myelin protein, the proteolipid
protein (PLP) and has been reported to be down-regulated in a
number of previous studies of schizophrenia [19,36,66]. These two
isoforms of PLP1 arise from differential use of two 59 splice sites in
exon 3, with the upstream site used for production of DM20 and
the downstream splice site for PLP mRNA [67]. Although the
functional difference between PLP and DM20 for the develop-
ment of compact myelin remains to be elucidated, it has been
reported that both forms are coordinately expressed during early
and late stages of myelination. During embryonic stages of
development, DM20 is the predominant product [68,69], but is
overtaken in postnatal stage by PLP, which is highly expressed in
oligodendrocytes [70]. This observation is consistent with our
detection of 78.5% and 83.4% of mRNA isoform encoding PLP in
both control and case, respectively. It has also been suggested that
DM20 and PLP may be identical in topology, but differ in the
conformation due to the extra 35 amino acid cytoplasmic peptide
in PLP [71]. This peptide with the normal function of detecting
conformational changes and triggering intracellular events such as
membrane compaction, imparts a susceptibility to mutations in
extracellular domains. The functional significance of the two
distinct isoforms in relation to schizophrenia warrants further
investigation.
A few limitations concerning the use of postmortem brain tissue
should be noted here. First, even though all the variables thought
to influence RNA integrity and gene expression were controlled
for as much as possible in this study, we cannot completely rule out
the impact of antipsychotic medication on changes in gene
expression in post-mortem brain tissue. Furthermore, two of the
schizophrenia subjects died as a result of suicide, which may
potentially contribute other changes to the transcriptome that are
independent of the underlying neuropsychiatric diagnosis. It is also
possible that some of the results reflect differences in the ratios of
various cell types in the tissue as a consequence of differential
shrinkage in specific cell types.
In summary, this is the first study to comprehensively profile
mRNA expression in STG in schizophrenia using ultra high-
throughput sequencing technology. The predominant change in
gene expression pattern accorded well with previous microarray
studies in its characterisation of schizophrenia as a disease of
synaptic, oligodendroglial, and metabolic origin [72]. In contrast
to expression by hybridisation, the sequencing approach demon-
strated greater sensitivity and specificity. This enabled us to reveal
the significance of the SNARE complex in synaptic abnormalities
Figure 5. Schematic showing the organisation and synaptic location of SNARE complexs and their associated proteins involved in
synaptic vesicle docking. The SNARE associated proteins encoded by 12 genes shown here to have significantly altered expression in
schizophrenia are highlighted by red asterisks and include SNAP25, synaptobrevin encoded by VAMP1, complexins encoded by CPLX1 and CPLX2,
synaptotagmins encoded by SYT1, SYT2, and SYT3, synapsins encoded by SYN2, synaptophysin encoded by SYP, RIMS3, NSF, and SNAP encoded by
NAPA. This shows the potential for dysregulation of synaptic vesicle docking and neurotransmitter release in the STG in schizophrenia. This figure is
adapted from PANTHER pathway p05734 synaptic vesicle trafficking (http://www.pantherdb.org/).
doi:10.1371/journal.pone.0036351.g005
Sequencing of STG Transcriptome in Schizophrenia
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e36351and indicated a schizophrenia candidate gene DCLK1 believed to
be involved in neuronal development. It also enabled the detection
of novel disease-associated alternative splicing and promoter
usage, suggesting that aberrant RNA processing could play a
significant role in the complex pathophysiology of schizophrenia.
Systematic investigation and functional analysis of alternative
splicing and promoter usage in relation to the neuropathology of
schizophrenia is needed to advance our current understanding of
the disease pathophysiology and will no doubt comprise an
essential part to future drug discovery efforts.
Materials and Methods
Sample preparation
Blocks of fresh frozen postmortem STG tissue from 9 subjects
with schizophrenia and 9 non-psychiatric controls were sourced
from the NSW Tissue Resource Centre, The University of
Sydney, Australia. In all cases, a diagnosis of schizophrenia in
accordance with DSM-IV criteria was confirmed by medical file
review using the Item Group Checklist of the Schedules for
Clinical Assessment in Neuropsychiatry and the Diagnostic
Instrument for Brain Studies. Written consent was obtained from
the next of kin and subjects with a significant history of drug or
alcohol abuse, or other conditions that might have influenced
agonal state were excluded. Control subjects with a history of
alcoholism or suicide were also excluded. Grey matter dissected
from STG blocks were from male Caucasian subjects, with
schizophrenia and non-psychiatric controls all from the left
hemisphere and matched for age, PMI and pH (Table 1).
Differences in the age, PMI, pH, and RQI between cases and
controls were not statistically significant (all p.0.05 by Student’s t-
test). This clinical information as well as duration of illness,
medication, cause of death and toxicology is shown in Table 1.
Cortical grey matter was dissected from the outer edge of tissue
blocks obtained from the most caudal coronal brain slice (1 cm)
containing the STG (Brodmann’s Area 22). Dissections were
performed blind on coded tissue blocks such that disease status was
not identifiable during this procedure. Samples were recovered
using a fine diameter tissue punch and scalpel as described
previously [73,74]. For each sample, 50–60 mg grey matter was
immediately processed in 1 ml Trizol reagent and the total RNA
was extracted according to the manufacturer’s instructions
(Invitrogen). After DNase treatment, the RNA concentration
and integrity was determined using an Experion microcapillary
electrophoresis instrument (BioRad, USA). All samples had RNA
Quality Indicator (RQI) values $6.0 and thus were considered
suitable for the analysis (Table 1). This study was approved by the
Figure 6. Alternative splicing, promoter usage, and SNP rs2296645 for the DCLK1 gene. (A) DCLK1 transcriptional isoforms ENST379892,
ENST360631, ENST379893, and ENST399319 are detected in both schizophrenia subjects and controls. ENST379892 and ENST360631 have the same
transcription start site TSSIII; ENST379893 and ENST399319 are initiated at TSSI and TSSII, respectively. (B) The location and nucleotide composition of
the SNP rs2296645 in the DCLK1 gene. (C) Altered expression levels of the 4 isoforms of DCLK1 between schizophrenia subjects and controls. (D)
Relative changes of the abundance of ENST360631 and ENST379892 from TSSIII between cases and controls. Numbers indicate the percentage of the
isoform. (E) Increased usage of TSSIII and decreased usage in TSSI in the DCLK1 gene in schizophrenia subjects compared to controls. Numbers
indicate the percentage of the promoter usage.
doi:10.1371/journal.pone.0036351.g006
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Australia.
Library preparation and sequencing
For the preparation of the mRNA library, poly-A containing
mRNA was purified from 10 mg total RNA using streptavidin-
coated magnetic beads (Illumina). After thermal fragmentation,
the cleaved mRNA fragments were reverse transcribed and then
converted into double strand cDNA. Following end repair and A-
tailing, adapters complementary to sequencing primers were
ligated to the ends of DNA fragments. The ligation products were
further purified on 2% agarose gels and 200–250 bp fragments
were selected for downstream enrichment by 15 cycles of PCR
followed by purification using QIAquick PCR purification kit
(Qiagen). The enriched libraries were diluted with Elution Buffer
to a final concentration of 10 nM. Each sample (7 pM
concentration) was subjected to 76 cycles of sequencing from a
single end in one lane of Illumina Genome Analyzer II. The
mRNA sequencing dataset has been submitted to ArrayExpress
(Accession Number E-MTAB-1030).
Pre-processing and mapping of RNA-Seq reads using
TopHat
The extraction of 76 bp length reads was achieved using
Bustard (Illumina Pipeline v1.3). For each sample, reads with
quality score 0 were filtered out and all the reads that passed
filtering were used to generate a complete FASTQ file (sequence
reads along with quality information in Phred format). This
FASTQ file was then mapped to UCSC H. sapiens reference
genome (build hg18) using TopHat v1.0.13 with default
parameters [75], which calls Bowtie v0.12.5 to perform the
alignment [76]. The pre-built index of UCSC H. sapiens hg18 was
downloaded from TopHat home page (http://tophat.cbcb.umd.
edu/index.html) and used as the reference genome. TopHat first
splits reads into shorter segments, then Bowtie reports successfully
mapped segments which have no more than 2 mismatches. Using
this initial mapping with each segment having no more than 10
alignments by default, TopHat identified potential exons and built
a database of possible splice junctions and then align unmapped
segments again with possible splices.
Transcript assembly and quantification using Cufflinks
The transcript assembly and quantification were accomplished
by Cufflinks suite, which assembles aligned reads into transcripts
and measures their relative abundance. Gene expression levels
were quantified as the number of reads mapping to a gene divided
by the gene length in kilobases and by the total number of mapped
reads in millions, designated RPKM units. By taking into account
the variations of gene length and the total mapped number of
sequencing reads, the RPKM measure gives normalized values of
gene expression, which enabled transparent comparisons between
samples [77]. In each case the aligned read files generated by
TopHat (one SAM file for each sample) were then supplied to
Cuffdiff v0.9.3 [78] along with the GTF file containing Ensembl
Genes annotation downloaded from UCSC Genome Browser for
assembly hg18 [79]. Aligned reads were then subjected to quartile
normalization before determining their differential expression in
RPKM to a false discovery rate (FDR) of 0.05. This analysis
enabled concurrent testing for differential expression and regula-
tion of transcript isoforms at nucleotide resolution. From this
information, changes in the relative abundance of transcripts
sharing a common transcription start site (TSS) were used to
investigate alternative splicing events. Similarly, changes in the
relative abundance of isoforms with different genomic origins were
used to identify alternative promoter usage within a gene. The
influence of non-diagnosis demographic parameters (age, pH,
pMI, and RQI) on gene expression were further examined by
analysis of covariance (ANCOVA) which showed no significant
difference (all adjusted p.0.05) between each demographic
parameter and differential gene expression across all samples.
Validation of differentially expressed genes by qPCR
Validation of DEGs was performed by qPCR using TaqMan
gene expression assays (Applied Biosystems, Life Technologies,
USA). Briefly, 500 ng of total cellular RNA was treated with
DNase I and reverse transcription was performed with Superscript
II reverse transcriptase (both Invitrogen, Life Technologies, USA)
as described previously [80]. Three genes were selected for
validation on the basis of strong differential expression and/or
biological significance (BTG2 Hs00198887_m1; DUSP1
Hs00610256_g1; EGR4 Hs04187165_g1). Triplicate reactions
were set up in a 96-well format using the epMotion 5070
automated pipetting system (Eppendorf, Germany) and carried
out using the Applied Biosystems 7500 real-time PCR machine.
Gene expression was normalized to the geometric mean of
controls b-actin (ACTB, Hs99999903_m1) and b-glucuronidase
(GUSB, Hs99999908_m1) and relative gene expression was
calculated using the 2
2(ddCt) method. Gene expression values
were Spearman correlated against variables such as age, pH and
PMI and those with significant correlations (p,0.05) were
covaried for using ANCOVA. For all others, differential gene
expression was assessed using the Student’s t-test with the
threshold for significance at p,0.05.
Functional analysis of differentially expressed genes
The differentially expressed genes identified by Cuffdiff were
subjected to gene ontology enrichment analysis using GOseq [81].
By taking into account transcript length and read count bias in
sequencing data, GOseq has been shown to be able to identify
more relevant biological categories than existing methods designed
for microarray such as DAVID and GoMiner. However, as GO
terms are derived from hierarchical functional annotation systems,
the redundancy problem of the enrichment results, such as
children terms partially redundant with their parents, is particu-
larly prominent. This problem was also reflected on the list of
more than 50 enriched GO terms (FDR,0.05) we obtained,
which required some form of organization of the GO terms for the
interpretation of the underlying biological themes. To this end,
EnrichmentMap, a freely available and open-source plugin for the
Cytoscape network visualization and analysis software, was used to
organise enriched GO terms as a weighted similarity network
[37,82].
The enrichment GO file obtained from GOseq was first loaded
in the EnrichmetMap and filtered for the significance of GO
enrichment according to the FDR thresholds (stringent cut off:
FDR,0.05; relaxed cut off: FDR,0.4) [37]. Then the overlap
measure between each GO term was computed according to the
Jaccard coefficient (the more overlapping, the higher of the
Jaccard coefficient), and GO terms were only linked if their
Jaccard coefficient was above 0.8 (default conservative cut off:
Jaccard threshold.0.5). Significantly enriched GO terms repre-
sented as nodes and thickness of links indicative of the Jaccard
coefficient were automatically arranged in the map using the
Cytoscape force directed layout and weighted mode, so that highly
similar GO terms were placed close together to facilitate the
cluster identification and interpretation of the biological functions.
The GO terms within the same functional cluster in the network
Sequencing of STG Transcriptome in Schizophrenia
PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e36351were then combined to derive genes that contributed to the
enrichment of these GO terms (core enrichment genes).
Supporting Information
Table S1 Differentially expressed genes between
schizophrenia cases and controls.
(XLS)
Table S2 Enriched GO terms in differentially expressed
genes.
(XLS)
Table S3 Differentially expressed genes contributed to
the enrichment of 3 GO terms in cluster 4 neurotrans-
mission related functions.
(XLS)
Table S4 Differentially expressed genes contributed to
the enrichment of 7 GO terms in cluster 5 synaptic
vesicle trafficking.
(XLS)
Table S5 Differentially expressed genes contributed to
the enrichment of 12 GO terms in cluster 6 neural
development.
(XLS)
Table S6 Genes with significant alternative promoter
usage (FDR,0.05) between schizophrenia cases and
controls.
(XLS)
Table S7 Genes with significant alternative splicing
(FDR,0.05) between schizophrenia cases and controls.
(XLS)
Acknowledgments
We acknowledge David Montgomery and the Academic and Research
Computing Service (ARCS) at the University of Newcastle, for technical
help with the Linux server and installation/maintenance of academic
software for sequencing analysis. Tissues were received from the Australian
Brain Donor Program’s NSW Tissue Resource Centre, supported by The
University of Sydney, National Health and Medical Research Council of
Australia, Schizophrenia Research Institute, and the National Institute of
Alcohol Abuse and Alcoholism.
Author Contributions
Conceived and designed the experiments: MC JQW. Performed the
experiments: JQW NB. Analyzed the data: JQW XW. Contributed
reagents/materials/analysis tools: JQW XW PT MC. Wrote the paper:
JQW XW PT RS VC MC. Read and approved the final manuscript: JQW
XW NB PT RS VC MC.
References
1. Carpenter WT, Jr., Buchanan RW (1994) Schizophrenia. N Engl J Med 330:
681–690.
2. Lewis DA, Levitt P (2002) Schizophrenia as a disorder of neurodevelopment.
Annu Rev Neurosci 25: 409–432.
3. Marenco S, Weinberger DR (2000) The neurodevelopmental hypothesis of
schizophrenia: following a trail of evidence from cradle to grave. Dev
Psychopathol 12: 501–527.
4. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, et al. (2001) Genome-wide
expression analysis reveals dysregulation of myelination-related genes in chronic
schizophrenia. Proc Natl Acad Sci U S A 98: 4746–4751.
5. Iwamoto K, Bundo M, Kato T (2005) Altered expression of mitochondria-
related genes in postmortem brains of patients with bipolar disorder or
schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol
Genet 14: 241–253.
6. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P (2002) Gene expression
profiling reveals alterations of specific metabolic pathways in schizophrenia.
J Neurosci 22: 2718–2729.
7. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000) Molecular
characterization of schizophrenia viewed by microarray analysis of gene
expression in prefrontal cortex. Neuron 28: 53–67.
8. Mirnics K, Middleton FA, Lewis DA, Levitt P (2001) Analysis of complex brain
disorders with gene expression microarrays: schizophrenia as a disease of the
synapse. Trends Neurosci 24: 479–486.
9. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, et al. (2003)
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:
798–805.
10. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001) Disease-
specific changes in regulator of G-protein signaling 4 (RGS4) expression in
schizophrenia. Mol Psychiatry 6: 293–301.
11. Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, et al. (2002)
Microarray analysis of gene expression in the prefrontal cortex in schizophrenia:
a preliminary study. Schizophr Res 58: 11–20.
12. Katsel P, Davis KL, Gorman JM, Haroutunian V (2005) Variations in
differential gene expression patterns across multiple brain regions in schizo-
phrenia. Schizophr Res 77: 241–252.
13. Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, et al. (2002) Gene
expression analysis in schizophrenia: reproducible up-regulation of several
members of the apolipoprotein L family located in a high-susceptibility locus for
schizophrenia on chromosome 22. Proc Natl Acad Sci U S A 99: 4680–4685.
14. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH, 3rd, et al. (2001)
Application of cDNA microarrays to examine gene expression differences in
schizophrenia. Brain Res Bull 55: 641–650.
15. Weidenhofer J, Bowden NA, Scott RJ, Tooney PA (2006) Altered gene
expression in the amygdala in schizophrenia: up-regulation of genes located in
the cytomatrix active zone. Mol Cell Neurosci 31: 243–250.
16. Chung C, Tallerico T, Seeman P (2003) Schizophrenia hippocampus has
elevated expression of chondrex glycoprotein gene. Synapse 50: 29–34.
17. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, et al. (2005) Deficient
hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial
genes in multiple schizophrenia cohorts. Biol Psychiatry 58: 85–96.
18. McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, et al.
(2007) Expression of transcripts for myelination-related genes in the anterior
cingulate cortex in schizophrenia. Schizophr Res 90: 15–27.
19. Aston C, Jiang L, Sokolov BP (2004) Microarray analysis of postmortem
temporal cortex from patients with schizophrenia. J Neurosci Res 77: 858–866.
20. Rajarethinam RP, DeQuardo JR, Nalepa R, Tandon R (2000) Superior
temporal gyrus in schizophrenia: a volumetric magnetic resonance imaging
study. Schizophr Res 41: 303–312.
21. Honea R, Crow TJ, Passingham D, Mackay CE (2005) Regional deficits in brain
volume in schizophrenia: a meta-analysis of voxel-based morphometry studies.
Am J Psychiatry 162: 2233–2245.
22. Bowden NA, Scott RJ, Tooney PA (2008) Altered gene expression in the
superior temporal gyrus in schizophrenia. BMC Genomics 9: 199.
23. Aston C, Jiang L, Sokolov BP (2005) Transcriptional profiling reveals evidence
for signaling and oligodendroglial abnormalities in the temporal cortex from
patients with major depressive disorder. Mol Psychiatry 10: 309–322.
24. Horesh Y, Katsel P, Haroutunian V, Domany E (2011) Gene expression
signature is shared by patients with Alzheimer’s disease and schizophrenia at the
superior temporal gyrus. Eur J Neurol 18: 410–424.
25. Morozova O, Marra MA (2008) Applications of next-generation sequencing
technologies in functional genomics. Genomics 92: 255–264.
26. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y (2008) RNA-seq: an
assessment of technical reproducibility and comparison with gene expression
arrays. Genome Res 18: 1509–1517.
27. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, et al. (2008) A
global view of gene activity and alternative splicing by deep sequencing of the
human transcriptome. Science 321: 956–960.
28. Richard H, Schulz MH, Sultan M, Nurnberger A, Schrinner S, et al. (2010)
Prediction of alternative isoforms from exon expression levels in RNA-Seq
experiments. Nucleic Acids Res 38: e112.
29. Honer WG, Falkai P, Bayer TA, Xie J, Hu L, et al. (2002) Abnormalities of
SNARE mechanism proteins in anterior frontal cortex in severe mental illness.
Cereb Cortex 12: 349–356.
30. Young CE, Arima K, Xie J, Hu L, Beach TG, et al. (1998) SNAP-25 deficit and
hippocampal connectivity in schizophrenia. Cereb Cortex 8: 261–268.
31. Gabriel SM, Haroutunian V, Powchik P, Honer WG, Davidson M, et al. (1997)
Increased concentrations of presynaptic proteins in the cingulate cortex of
subjects with schizophrenia. Arch Gen Psychiatry 54: 559–566.
32. Mukaetova-Ladinska EB, Hurt J, Honer WG, Harrington CR, Wischik CM
(2002) Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic
schizophrenics. Neurosci Lett 317: 161–165.
33. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, et al. (2008)
Systematic meta-analyses and field synopsis of genetic association studies in
schizophrenia: the SzGene database. Nat Genet 40: 827–834.
Sequencing of STG Transcriptome in Schizophrenia
PLoS ONE | www.plosone.org 13 April 2012 | Volume 7 | Issue 4 | e3635134. Altar CA, Vawter MP, Ginsberg SD (2009) Target identification for CNS
diseases by transcriptional profiling. Neuropsychopharmacology 34: 18–54.
35. Sequeira PA, Martin MV, Vawter MP (2012) The first decade and beyond of
transcriptional profiling in schizophrenia. Neurobiol Dis 45: 23–36.
36. Haroutunian V, Katsel P, Dracheva S, Stewart DG, Davis KL (2007) Variations in
oligodendrocyte-related gene expression across multiple cortical regions: implica-
tions for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol
10: 565–573.
37. Merico D, Isserlin R, Stueker O, Emili A, Bader GD (2010) Enrichment map: a
network-based method for gene-set enrichment visualization and interpretation.
PLoS One 5: e13984.
38. Deng X, Takaki H, Wang L, Kuroki T, Nakahara T, et al. (2011) Positive
association of phencyclidine-responsive genes, PDE4A and PLAT, with
schizophrenia. Am J Med Genet B Neuropsychiatr Genet 156B: 850–858.
39. Sollner T, Whiteheart SW, Brunner M, Erdjument-Bromage H, Geromanos S,
et al. (1993) SNAP receptors implicated in vesicle targeting and fusion. Nature
362: 318–324.
40. Seiler F, Malsam J, Krause JM, Sollner TH (2009) A role of complexin-lipid
interactions in membrane fusion. FEBS Lett 583: 2343–2348.
41. Martens S, Kozlov MM, McMahon HT (2007) How synaptotagmin promotes
membrane fusion. Science 316: 1205–1208.
42. Ferreira A, Rapoport M, Ferreira A, Chin LS, Li L, et al. (2002) The synapsins:
beyond the regulation of neurotransmitter release. Cell Mol Life Sci 59:
589–595.
43. Edelmann L, Hanson PI, Chapman ER, Jahn R (1995) Synaptobrevin binding
to synaptophysin: a potential mechanism for controlling the exocytotic fusion
machine. Embo J 14: 224–231.
44. Uriu Y, Kiyonaka S, Miki T, Yagi M, Akiyama S, et al. (2010) Rab3-interacting
molecule gamma isoforms lacking the Rab3-binding domain induce long lasting
currents but block neurotransmitter vesicle anchoring in voltage-dependent P/
Q-type Ca2+ channels. J Biol Chem 285: 21750–21767.
45. Block MR, Glick BS, Wilcox CA, Wieland FT, Rothman JE (1988) Purification
of an N-ethylmaleimide-sensitive protein catalyzing vesicular transport. Proc
Natl Acad Sci U S A 85: 7852–7856.
46. Barakauskas VE, Beasley CL, Barr AM, Ypsilanti AR, Li HY, et al. (2010) A
novel mechanism and treatment target for presynaptic abnormalities in specific
striatal regions in schizophrenia. Neuropsychopharmacology 35: 1226–1238.
47. Chana G, Lucero G, Salaria S, Lozach J, Du P, et al. (2009) Upregulation of
NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine.
Schizophr Res 113: 273–276.
48. Sommer JU, Schmitt A, Heck M, Schaeffer EL, Fendt M, et al. (2010)
Differential expression of presynaptic genes in a rat model of postnatal hypoxia:
relevance to schizophrenia. Eur Arch Psychiatry Clin Neurosci 260 Suppl 2:
S81–89.
49. Kontkanen O, Toronen P, Lakso M, Wong G, Castren E (2002) Antipsychotic
drug treatment induces differential gene expression in the rat cortex.
J Neurochem 83: 1043–1053.
50. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, et al. (1999)
Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex
in schizophrenia: a possible neurochemical basis for ‘hypofrontality’. Mol
Psychiatry 4: 39–45.
51. Mudge J, Miller NA, Khrebtukova I, Lindquist IE, May GD, et al. (2008)
Genomic convergence analysis of schizophrenia: mRNA sequencing reveals
altered synaptic vesicular transport in post-mortem cerebellum. PLoS One 3:
e3625.
52. Mirnics K, Levitt P, Lewis DA (2006) Critical appraisal of DNA microarrays in
psychiatric genomics. Biol Psychiatry 60: 163–176.
53. Duncan CE, Chetcuti AF, Schofield PR (2008) Coregulation of genes in the
mouse brain following treatment with clozapine, haloperidol, or olanzapine
implicates altered potassium channel subunit expression in the mechanism of
antipsychotic drug action. Psychiatr Genet 18: 226–239.
54. Zink M, Schmitt A, May B, Muller B, Demirakca T, et al. (2004) Differential
effects of long-term treatment with clozapine or haloperidol on GABAA receptor
binding and GAD67 expression. Schizophr Res 66: 151–157.
55. Schachner M, Bartsch U (2000) Multiple functions of the myelin-associated
glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia 29:
154–165.
56. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. (2004)
Mitochondrial dysfunction in schizophrenia: evidence for compromised brain
metabolism and oxidative stress. Mol Psychiatry 9: 684–697, 643.
57. MacDonald ML, Naydenov A, Chu M, Matzilevich D, Konradi C (2006)
Decrease in creatine kinase messenger RNA expression in the hippocampus and
dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disord 8: 255–264.
58. Voos W, Rottgers K (2002) Molecular chaperones as essential mediators of
mitochondrial biogenesis. Biochim Biophys Acta 1592: 51–62.
59. Aitken A, Baxter H, Dubois T, Clokie S, Mackie S, et al. (2002) Specificity of 14-
3-3 isoform dimer interactions and phosphorylation. Biochem Soc Trans 30:
351–360.
60. Schwab SG, Hallmayer J, Albus M, Lerer B, Eckstein GN, et al. (2000) A
genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families
with affected siblings: support for loci on chromosome 10p and 6. Mol
Psychiatry 5: 638–649.
61. Koizumi H (2007) Physiological function of the DCX family in brain
development. Seikagaku 79: 1134–1139.
62. Burgess HA, Reiner O (2000) Doublecortin-like kinase is associated with
microtubules in neuronal growth cones. Mol Cell Neurosci 16: 529–541.
63. Silverman MA, Benard O, Jaaro H, Rattner A, Citri Y, et al. (1999) CPG16, a
novel protein serine/threonine kinase downstream of cAMP-dependent protein
kinase. J Biol Chem 274: 2631–2636.
64. Burgess HA, Martinez S, Reiner O (1999) KIAA0369, doublecortin-like kinase,
is expressed during brain development. J Neurosci Res 58: 567–575.
65. Verissimo CS, Molenaar JJ, Meerman J, Puigvert JC, Lamers F, et al. (2010)
Silencing of the microtubule-associated proteins doublecortin-like and double-
cortin-like kinase-long induces apoptosis in neuroblastoma cells. Endocr Relat
Cancer 17: 399–414.
66. Sokolov BP (2007) Oligodendroglial abnormalities in schizophrenia, mood
disorders and substance abuse. Comorbidity, shared traits, or molecular
phenocopies? Int J Neuropsychopharmacol 10: 547–555.
67. Nave KA, Lai C, Bloom FE, Milner RJ (1987) Splice site selection in the
proteolipid protein (PLP) gene transcript and primary structure of the DM-20
protein of central nervous system myelin. Proc Natl Acad Sci U S A 84:
5665–5669.
68. Sporkel O, Uschkureit T, Bussow H, Stoffel W (2002) Oligodendrocytes
expressing exclusively the DM20 isoform of the proteolipid protein gene:
myelination and development. Glia 37: 19–30.
69. Jacobs EC, Bongarzone ER, Campagnoni CW, Campagnoni AT (2004)
Embryonic expression of the soma-restricted products of the myelin proteolipid
gene in motor neurons and muscle. Neurochem Res 29: 997–1002.
70. Jahn O, Tenzer S, Werner HB (2009) Myelin proteomics: molecular anatomy of
an insulating sheath. Mol Neurobiol 40: 55–72.
71. Gow A, Gragerov A, Gard A, Colman DR, Lazzarini RA (1997) Conservation
of topology, but not conformation, of the proteolipid proteins of the myelin
sheath. J Neurosci 17: 181–189.
72. Faludi G, Mirnics K (2011) Synaptic changes in the brain of subjects with
schizophrenia. Int J Dev Neurosci 2011: 4.
73. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ (2010)
Schizophrenia is associated with an increase in cortical microRNA biogenesis.
Mol Psychiatry 15: 1176–1189.
74. Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, et al. (2008)
Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum
Mol Genet 17: 1156–1168.
75. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: discovering splice junctions
with RNA-Seq. Bioinformatics 25: 1105–1111.
76. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome Biol
10: R25.
77. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and
quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621–628.
78. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010)
Transcript assembly and quantification by RNA-Seq reveals unannotated
transcripts and isoform switching during cell differentiation. Nat Biotechnol 28:
511–515.
79. Pruitt KD, Tatusova T, Klimke W, Maglott DR (2009) NCBI Reference
Sequences: current status, policy and new initiatives. Nucleic Acids Res 37:
D32–36.
80. Santarelli DM, Beveridge NJ, Tooney PA, Cairns MJ (2011) Upregulation of
dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann
area 46 in schizophrenia. Biol Psychiatry 69: 180–187.
81. Young MD, Wakefield MJ, Smyth GK, Oshlack A (2010) Gene ontology
analysis for RNA-seq: accounting for selection bias. Genome Biol 11: R14.
82. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, et al. (2007)
Integration of biological networks and gene expression data using Cytoscape.
Nat Protoc 2: 2366–2382.
Sequencing of STG Transcriptome in Schizophrenia
PLoS ONE | www.plosone.org 14 April 2012 | Volume 7 | Issue 4 | e36351